Bicara Therapeutics Inc. (BCAX) Stock

NASDAQ: BCAXHealthcare company in the biotechnology industry, based in Boston, MA.

Bicara Therapeutics stock price chart

BCAX interactive chart →

BCAX stock quote & key statistics

Bicara Therapeutics earnings per share

Income →
Earnings per share

Bicara Therapeutics revenue & net income

Income →
RevenueNet income

Bicara Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$137.9M-$2.53
FY2024$0-$68.0M-$2.44
FY2023$0-$52.0M—
FY2022$0-$37.8M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Bicara Therapeutics stock FAQ

What is the Bicara Therapeutics stock ticker symbol?

Bicara Therapeutics Inc. trades on the NASDAQ under the ticker symbol BCAX.

What sector and industry is Bicara Therapeutics in?

Bicara Therapeutics Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Bicara Therapeutics have?

Bicara Therapeutics Inc. has about 103 full-time employees.

What were Bicara Therapeutics's revenue and earnings last fiscal year?

Bicara Therapeutics reported revenue of $0 and net income of -$137.9M in fiscal 2025, with earnings per share of -$2.53.

Is Bicara Therapeutics in the Russell 2000?

Yes. Bicara Therapeutics Inc. (BCAX) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Bicara Therapeutics go public?

Bicara Therapeutics stock began trading on September 13, 2024.

Russell 2000 Biotechnology stocks

All Russell 2000 →